Free Trial

Actinium Pharmaceuticals (ATNM) Competitors

Actinium Pharmaceuticals logo
$1.79 -0.03 (-1.65%)
Closing price 04:00 PM Eastern
Extended Trading
$1.78 -0.01 (-0.56%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ATNM vs. ALMS, CTMX, SXTC, VYGR, KYTX, GNFT, DRUG, GALT, IMAB, and TLSA

Should you be buying Actinium Pharmaceuticals stock or one of its competitors? The main competitors of Actinium Pharmaceuticals include Alumis (ALMS), CytomX Therapeutics (CTMX), China SXT Pharmaceuticals (SXTC), Voyager Therapeutics (VYGR), Kyverna Therapeutics (KYTX), GENFIT (GNFT), Bright Minds Biosciences (DRUG), Galectin Therapeutics (GALT), I-Mab (IMAB), and Tiziana Life Sciences (TLSA). These companies are all part of the "pharmaceutical products" industry.

Actinium Pharmaceuticals vs. Its Competitors

Alumis (NASDAQ:ALMS) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 40.7% of Alumis shares are owned by company insiders. Comparatively, 6.0% of Actinium Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Alumis currently has a consensus price target of $19.80, suggesting a potential upside of 410.31%. Actinium Pharmaceuticals has a consensus price target of $4.00, suggesting a potential upside of 123.46%. Given Alumis' stronger consensus rating and higher possible upside, research analysts plainly believe Alumis is more favorable than Actinium Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alumis
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.14
Actinium Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

Actinium Pharmaceuticals' return on equity of -100.85% beat Alumis' return on equity.

Company Net Margins Return on Equity Return on Assets
AlumisN/A -406.27% -107.29%
Actinium Pharmaceuticals N/A -100.85%-47.89%

In the previous week, Alumis had 6 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 7 mentions for Alumis and 1 mentions for Actinium Pharmaceuticals. Actinium Pharmaceuticals' average media sentiment score of 1.11 beat Alumis' score of 0.92 indicating that Actinium Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alumis
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Actinium Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AlumisN/AN/A-$294.23MN/AN/A
Actinium PharmaceuticalsN/AN/A-$48.82M-$1.47-1.22

Summary

Alumis beats Actinium Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Get Actinium Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATNM vs. The Competition

MetricActinium PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$55.84M$776.90M$5.70B$21.12B
Dividend YieldN/A4.84%4.69%3.60%
P/E Ratio-1.291.1821.1927.40
Price / SalesN/A25.35461.3060.38
Price / CashN/A19.5636.2222.92
Price / Book1.376.798.664.69
Net Income-$48.82M-$4.32M$3.25B$995.51M
7 Day Performance4.68%1.33%4.20%1.64%
1 Month Performance8.48%3.74%10.82%5.92%
1 Year PerformanceN/A8.18%34.70%11.50%

Actinium Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATNM
Actinium Pharmaceuticals
2.4567 of 5 stars
$1.79
-1.6%
$4.00
+123.5%
N/A$55.84MN/A-1.2930Positive News
ALMS
Alumis
3.2508 of 5 stars
$3.60
+2.3%
$22.86
+534.9%
-69.9%$195.88MN/A0.00N/ANews Coverage
Analyst Forecast
Gap Up
CTMX
CytomX Therapeutics
4.2271 of 5 stars
$2.39
-1.2%
$5.33
+123.2%
+70.7%$192.68M$138.10M4.98170News Coverage
Positive News
Gap Up
SXTC
China SXT Pharmaceuticals
1.2378 of 5 stars
$1.66
-5.1%
N/A-82.2%$192.61M$1.93M0.0090Positive News
Gap Up
VYGR
Voyager Therapeutics
3.8701 of 5 stars
$3.43
-1.7%
$13.39
+290.4%
-62.8%$189.82M$80M-2.35100
KYTX
Kyverna Therapeutics
2.701 of 5 stars
$4.39
+8.9%
$18.50
+321.4%
-52.5%$189.74M$7.03M-1.3096
GNFT
GENFIT
2.4865 of 5 stars
$3.79
+3.8%
$13.00
+243.0%
-4.0%$189.50M$76.77M0.00120Gap Down
DRUG
Bright Minds Biosciences
2.4522 of 5 stars
$25.65
+3.4%
$83.25
+224.6%
+2,459.2%$180.68MN/A-71.25N/ANews Coverage
Positive News
GALT
Galectin Therapeutics
2.4432 of 5 stars
$2.85
+13.5%
$6.00
+110.5%
+14.0%$180.38MN/A-3.969
IMAB
I-Mab
2.869 of 5 stars
$2.14
+0.5%
$6.00
+180.4%
+50.4%$174.75M$3.89M0.00380Gap Down
TLSA
Tiziana Life Sciences
1.2124 of 5 stars
$1.48
flat
N/A+74.0%$172.94MN/A0.008

Related Companies and Tools


This page (NYSE:ATNM) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners